There's never a shortage of losers in the stock market.

Let's take a closer look at five of this past week's biggest sinkers.

Company

Jan. 6

Weekly Loss

My Watchlist

BioMimetic Therapeutics (Nasdaq: BMTI) $2.00 (30%) Add
Spreadtrum Communications (Nasdaq: SPRD) $14.98 (28%) Add
Barnes & Noble (NYSE: BKS) $11.19 (23%) Add
Telestone Tech (Nasdaq: TSTC) $3.36 (19%) Add
Angie's List (Nasdaq: ANGI) $13.23 (18%) Add

Source: Barron's.

BioMimetic Therapeutics was the market's biggest loser, shedding nearly 30% of its value after its bone graft device was dealt a setback in the approval process from the Food and Drug Administration.

Mobile chip designer Spreadtrum took a hit -- with a 22% drop on Friday alone -- after RF Micro Devices pointed the finger at softening demand from its China-based customers.

Investors threw the book -- and Nook -- at Barnes & Noble after the company dramatically hosed down the guidance for its EBITDA and bottom-line results for its current fiscal year. The company's Nook business is going well, at least outside of disappointing sales for its entry-level e-reader. However, steep losses in that business find the bookseller exploring the separation of its two major businesses.

Telestone is another heartbreaker. The Beijing-based supplier of local access network solutions for communications networks updated its guidance for the fiscal year that just ended. Telestone sees revenue growth of just 15%, half the pace it had projected earlier. Did it really have to wait until the end of the year to publicly concede that point?

Finally, we have Angie's List fishing for referrals on a good pain healer. Analysts finally chimed in with public opinions on the company, and it wasn't pretty. Just three of the eight pros offered "buy" ratings, and those three helped take the company public two months ago.

It was a rough week for these five stocks. If you want to shake yesterday's losers and ride tomorrow's winners, a new special report reveals The Motley Fool's top stock for 2012. It's free, but only for a limited time so check it out now.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Longtime Fool contributor Rick Munarriz calls them as he sees them. He does not own shares in any of the stocks in this story. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.